Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics
Journal of Antimicrobial Chemotherapy · 19.09.2024 · 79 (Supplement_1) · i13-i25
DOI: 10.1093/jac/dkae282 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 19.09.2024. Verfasst von Shawn H MacVane und 1 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical Affairs-Microbiology, bioMérieux, Inc., Hazelwood, MO, USA. Hauptthemen laut MEDLINE: Microbial Sensitivity Tests, Anti-Bacterial Agents, Bacteremia. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: bioMérieux, Marcy-l'Étoile, Marcy-l’Étoile.
Abstract (Originalsprache)
Antimicrobial susceptibility testing (AST) is a core function of the clinical microbiology laboratory and is critical to the management of patients with bloodstream infections (BSIs) to facilitate optimal antibiotic therapy selection. Recent technological advances have resulted in several rapid methods for determining susceptibility direct from positive blood culture that can provide turnaround times in under 8 h, which is considerably shorter than conventional culture-based methods. As diagnostic results do not directly produce a medical intervention, actionability is a primary determinant of the effect these technologies have on antibiotic use and ultimately patient outcomes. Randomized controlled trials and observational studies consistently show that rapid AST significantly reduces time to results and improves antimicrobial therapy for patients with BSI across various methods, patient populations and organisms. To date, the clinical impact of rapid AST has been demonstrated in some observational studies, but randomized controlled trials have not been sufficiently powered to validate many of these findings. This article reviews various metrics that have been described in the literature to measure the impact of rapid AST on actionability, antibiotic exposure and patient outcomes, as well as highlighting how implementation and workflow processes can affect these metrics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Medical Affairs-Microbiology, bioMérieux, Inc., Hazelwood, MO, USA.
ORCID-Profile: Shawn H MacVane
Förderung
- bioMérieux
- Marcy-l'Étoile
- Marcy-l’Étoile
Zitieren
APA
MacVane, S. H., & Dwivedi, H. P. (2024). Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics. Journal of Antimicrobial Chemotherapy, 79(Supplement_1), i13-i25. https://doi.org/10.1093/jac/dkae282
Vancouver
MacVane SH, Dwivedi HP. Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics. Journal of Antimicrobial Chemotherapy. 2024;79(Supplement_1):i13-i25. doi:10.1093/jac/dkae282
BibTeX
@article{MacVane2024,
author = {MacVane, Shawn H and Dwivedi, Hari P},
title = {Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {Supplement_1},
pages = {i13--i25},
doi = {10.1093/jac/dkae282}
}
EUVIMED